Advanced or Metastatic Solid Tumors
Conditions
Brief summary
This is a phase I, open-label, multi-center, dose escalation and expansion study in advanced or metastatic solid tumor patients. The're are two goals set in this study: one is to explore the safety and tolerability of KGX101 when mono and combo with envafolimab in Chinese patients, the other is to determine recommended phase 2 dose of KGX101 mono and combo with envafolimab. Participants will: 1. Take drug KGX101 mono or combo with envafolimab every 3 weeks; 2. Visit the clinic for checkups and tests. Schedule will be about 6-8 times in the first month and then about every 3 weeks afterwards.
Interventions
DRUGKGX101 injection
KGX101 is a heterodimeric IL-12 prodrug with the C-terminus of IL-12 fused with ADCC-impaired IgG1 Fc and the N-terminus of IL-12 masked using the IL-12 binding domains of IL-12Rβ1 and IL-12Rβ2. KGX101 injection is a sterile, white or white-like lyophilized powder, supplied at 4.0 mg/vial for single use.
DRUGEnvafolimab
Envafolimab is a novel fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc fragment formulated for subcutaneous injection.
Sponsors
Kangabio AUSTRALIA LTD PTY
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Any histologically or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic and has failed standard of care, no further standard can be used, or standard of care is not fit; 2. Eastern cooperative oncology grous performance status of 0-1; 3. Has at least 1 measurable lesion per RECIST 1.1; 4. Has adequate organ and bone marrow function as per study which including hemoglobin \> 90 g/L, platelet count \>=100\*10e9/L, absolute meutrophil count \>=1.5\*10e9/L; 5. Life expectancy of at least 3 months; 6. Provision of signed and dated written inform consent prior to any study-related procedures, sampling and analyses.
Exclusion criteria
1. Active known second malignancy except adequately treated basal cell carcinoma, squamous cell skin cancer, in situ cervical cancer, breast cancer; 2. Patients with primary CNS malignancies; 3. Evidence of severe or uncontrolled systemic diseases, including: active infection, hypertension, chronically unhealed wound or ulcers; 4. Active autoimmnue disease requiring systemic treatment in the last 2 years, or immunodefiency which is on immunosuppressive therapy, chronic systemic or enteric steroid therapy; 5. History of pneumonitis, interstitial lung disease which require steroids or has current pneumonitis/ interstitial lung disease; 6. Any unresolved toxicities from prior therapy greater than CTCAE 5.0 grade 1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Numbers of participants with adverse events | From baseline to 30 days after the last dose administration. | AE will be collected to assess participants' safety after KGX101 monotherapy or combo with Envafolimab |
| Number of participants with dose limiting toxicities/DLT within DLT observation period | From Day1 after the first priming dose of KGX101 until 21 days post the first target dose ofKGX101 | DLT will be observed from start of the first priming dose of KGX101 until 21 days post the first target dose of KGX101 |
| Number of participants with changes of clinical lab abnormalities | From screening until 90 days post the last dose administration | Any changes in values of the clinical chemistry, hematology, coagulation and urinalysis will be evaluated |
| The maximum tolerated dose of KGX101 monotherapy and combination therapy with Envafolimab | From Day 1 post the first dosing until 21 days post the the first target dosing | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters: Maximum Concentration (Cmax) of total IL-12 | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| PK Parameters: Time of maximum observed concentration (Tmax)of total IL-12 | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| PK Parameters: Area under the curve (AUC) | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| PK Parameters: Half- life (T1 /2) | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| PK Parameters- Trough concentration (Ctrough) | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| PK Parameters- Systemic clearance (CL) | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| PK Parameters- Volume of distribution (Vd) | Part A: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until Day 1 of the last dose. | Part A- The PK schedule after the first and third target dose injection of KGX101 are as follows: pre-dose, 0 h, 2, 6, 24, 48, 72, 168 and 336hr post dose. Other sample collection timepoints include: pre-dose of each priming dose, pre-dose of other target dose; Part B- The PK schedule after Envafoliamb: pre-dose (1st, 2nd, 3rd and 4th treatment) and 72h ±1 h post the 1st Envafolimab treatment. |
| Immunogenicity- Anti-drug antibody (ADA) | Part A: From pre-dose of the first dose of KGX101 treatment until 90 days afrer the last dose. Part B: From pre-dose of the first dose of KGX101 treatment until 90 days after the last dose. | Samples will be collected to assess the immunogeniccity after each KGX101 treatment. |
| Number of participants with changes in the Overall Response (ORR) | From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post the last treatment. | — |
| Progression free survival (PFS) per RECIST 1.1 | From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post last treatment. | — |
| Overall survival | From Day 1 after the first dose of KGX101 till survival follow-up every 90 days post last treatment. | — |
Countries
China
Contacts
CONTACTJun Guo
PRINCIPAL_INVESTIGATORJun Guo
Beijing Cancer Hopspital
Outcome results
None listed